PriceTargets.com logo

ICON Public - ICLR Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $304.27
  • Forecasted Upside: 32.31%
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 10 Buy Ratings
  • 1 Strong Buy Ratings
$229.97 As of 10/30/2024 03:58 PM ET
▼ -2.43 (-1.05%)

This chart shows the closing price for ICLR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ICON Public Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ICLR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ICLR

Analyst Price Target is $304.27
▲ +32.31% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for ICON Public in the last 3 months. The average price target is $304.27, with a high forecast of $350.00 and a low forecast of $270.00. The average price target represents a 32.31% upside from the last price of $229.97.

This chart shows the closing price for ICLR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 14 polled investment analysts is to moderate buy stock in ICON Public. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 1 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2023
  • 1 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2023
  • 1 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2024
  • 1 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2024
  • 1 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2024
  • 1 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2024
  • 1 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2024

Latest Recommendations

  • 1 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/28/2024Truist FinancialLower TargetBuy ➝ Buy$363.00 ➝ $295.00
10/25/2024TD CowenLower TargetBuy ➝ Buy$369.00 ➝ $285.00
10/25/2024BarclaysLower TargetOverweight ➝ Overweight$330.00 ➝ $275.00
10/25/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$375.00 ➝ $280.00
10/25/2024The Goldman Sachs GroupLower TargetBuy ➝ Buy$370.00 ➝ $280.00
10/25/2024Leerink PartnersLower TargetOutperform ➝ Outperform$376.00 ➝ $270.00
10/24/2024Baird R WDowngradeStrong-Buy ➝ Hold
10/24/2024Robert W. BairdDowngradeOutperform ➝ Neutral$340.00 ➝ $340.00
10/15/2024BarclaysLower TargetOverweight ➝ Overweight$350.00 ➝ $330.00
10/14/2024Truist FinancialLower TargetBuy ➝ Buy$383.00 ➝ $363.00
10/14/2024Redburn AtlanticInitiated CoverageNeutral$311.00
10/8/2024Evercore ISILower TargetOutperform ➝ Outperform$360.00 ➝ $350.00
9/20/2024Robert W. BairdLower TargetOutperform ➝ Outperform$368.00 ➝ $340.00
9/18/2024Leerink PartnrsUpgradeStrong-Buy
9/18/2024Leerink PartnersInitiated CoverageOutperform$379.00
9/11/2024Robert W. BairdReiterated RatingOutperform ➝ Outperform$368.00 ➝ $368.00
9/11/2024Truist FinancialReiterated RatingBuy ➝ Buy$383.00 ➝ $383.00
7/26/2024BarclaysLower TargetOverweight ➝ Overweight$355.00 ➝ $350.00
7/26/2024Truist FinancialBoost TargetBuy ➝ Buy$367.00 ➝ $383.00
7/8/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$367.00 ➝ $376.00
6/6/2024The Goldman Sachs GroupInitiated CoverageBuy$370.00
5/31/2024William BlairReiterated RatingOutperform
5/31/2024TD CowenBoost TargetBuy ➝ Buy$349.00 ➝ $373.00
5/31/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$363.00 ➝ $367.00
4/26/2024Evercore ISILower TargetOutperform ➝ Outperform$350.00 ➝ $330.00
4/26/2024TD CowenBoost TargetBuy ➝ Buy$343.00 ➝ $349.00
4/26/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$362.00 ➝ $363.00
4/4/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$345.00 ➝ $362.00
4/4/2024MizuhoReiterated RatingBuy ➝ Buy$346.00
2/23/2024MizuhoBoost TargetBuy ➝ Buy$315.00 ➝ $346.00
2/23/2024Evercore ISIBoost TargetOutperform ➝ Outperform$325.00 ➝ $350.00
2/23/2024BarclaysBoost TargetOverweight ➝ Overweight$325.00 ➝ $355.00
2/23/2024Truist FinancialBoost TargetBuy ➝ Buy$357.00 ➝ $367.00
1/25/2024BarclaysBoost TargetOverweight ➝ Overweight$280.00 ➝ $325.00
12/20/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$295.00 ➝ $330.00
12/15/2023Truist FinancialInitiated CoverageBuy$357.00
12/11/2023CitigroupBoost TargetBuy ➝ Buy$300.00 ➝ $315.00
10/17/2023Robert W. BairdBoost TargetOutperform ➝ Outperform$278.00 ➝ $287.00
10/11/2023Evercore ISILower Target$290.00 ➝ $275.00
9/13/2023MizuhoReiterated RatingBuy ➝ Buy$274.00
9/13/2023TD CowenInitiated CoverageOutperform$306.00
7/28/2023BarclaysBoost TargetOverweight$250.00 ➝ $280.00
7/14/2023Deutsche Bank AktiengesellschaftBoost Target$280.00 ➝ $300.00
7/11/2023MizuhoBoost Target$250.00 ➝ $274.00
5/1/2023Robert W. BairdLower Target$280.00 ➝ $270.00
5/1/2023Wells Fargo & CompanyLower Target$245.00 ➝ $220.00
4/28/2023GuggenheimLower Target$271.00 ➝ $263.00
4/28/2023CitigroupLower Target$270.00 ➝ $250.00
4/4/2023BarclaysLower TargetOverweight$260.00 ➝ $250.00
2/24/2023Robert W. BairdBoost TargetOutperform$265.00 ➝ $285.00
1/20/2023GuggenheimBoost TargetBuy$255.00 ➝ $262.00
1/13/2023BarclaysUpgradeEqual Weight ➝ Overweight$215.00 ➝ $260.00
1/12/2023Robert W. BairdBoost TargetOutperform$260.00 ➝ $265.00
12/21/2022Robert W. BairdLower Target$265.00 ➝ $260.00
11/10/2022MizuhoLower TargetBuy$272.00 ➝ $250.00
11/9/2022Bank of AmericaUpgradeNeutral ➝ Buy$265.00 ➝ $260.00
10/18/2022Deutsche Bank AktiengesellschaftLower Target$295.00 ➝ $280.00
10/10/2022GuggenheimLower TargetBuy$278.00 ➝ $268.00
10/6/2022BarclaysLower TargetEqual Weight$240.00 ➝ $215.00
9/12/2022BarclaysLower TargetEqual Weight$260.00 ➝ $240.00
9/7/2022UBS GroupInitiated CoverageBuy$270.00
8/24/2022Credit Suisse GroupInitiated CoverageNeutral$260.00
7/29/2022Deutsche Bank AktiengesellschaftBoost Target$285.00 ➝ $295.00
7/28/2022William BlairReiterated RatingOutperform
7/14/2022Deutsche Bank AktiengesellschaftLower TargetBuy$310.00 ➝ $285.00
7/13/2022BarclaysLower TargetEqual Weight$250.00 ➝ $245.00
7/8/2022CitigroupLower TargetBuy$315.00 ➝ $290.00
5/23/2022GuggenheimInitiated CoverageBuy$285.00
5/13/2022Robert W. BairdReiterated RatingBuy$285.00
4/25/2022Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$280.00 ➝ $250.00
4/11/2022Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$234.00 ➝ $310.00
3/7/2022MizuhoLower TargetBuy$315.00 ➝ $272.00
2/25/2022Deutsche Bank AktiengesellschaftLower TargetHold$287.00 ➝ $235.00
2/23/2022BarclaysLower TargetEqual Weight$285.00 ➝ $255.00
2/23/2022CitigroupLower TargetBuy$340.00 ➝ $315.00
1/27/2022BarclaysLower TargetEqual Weight$315.00 ➝ $285.00
11/16/2021Deutsche Bank AktiengesellschaftBoost TargetHold$234.00 ➝ $287.00
11/5/2021BarclaysBoost TargetEqual Weight$240.00 ➝ $315.00
11/5/2021MizuhoBoost TargetBuy$242.00 ➝ $315.00
9/27/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$230.00 ➝ $320.00
9/14/2021Jefferies Financial GroupBoost TargetBuy$276.00 ➝ $302.00
7/26/2021Deutsche Bank AktiengesellschaftBoost TargetHold$212.00 ➝ $234.00
7/23/2021CitigroupUpgradeNeutral ➝ Buy$260.00
7/23/2021Wells Fargo & CompanyBoost TargetPositive ➝ Overweight$250.00 ➝ $280.00
7/23/2021Robert W. BairdBoost TargetOutperform$260.00 ➝ $265.00
7/20/2021Credit Suisse GroupBoost TargetOutperform$245.00 ➝ $250.00
7/14/2021CitigroupInitiated CoverageNeutral$220.00
5/3/2021MizuhoBoost TargetBuy$217.00 ➝ $242.00
4/29/2021Credit Suisse GroupBoost TargetOutperform$240.00 ➝ $245.00
4/29/2021Jefferies Financial GroupBoost TargetBuy$256.00 ➝ $267.00
4/13/2021Bank of AmericaInitiated CoverageNeutral
4/1/2021Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$200.00 ➝ $235.00
3/8/2021BarclaysInitiated CoverageEqual Weight$200.00
3/8/2021Robert W. BairdUpgradeNeutral ➝ Outperform$215.00
3/2/2021BarclaysInitiated CoverageEqual Weight$200.00
3/1/2021UBS GroupUpgradeNeutral ➝ Buy$207.00 ➝ $232.00
2/26/2021Truist FinancialUpgradeHold ➝ Buy$280.00
2/25/2021Deutsche Bank AktiengesellschaftBoost TargetHold$179.00 ➝ $208.00
10/23/2020Deutsche Bank AktiengesellschaftBoost TargetHold$170.00 ➝ $179.00
10/23/2020MizuhoBoost TargetBuy$195.00 ➝ $217.00
10/22/2020Credit Suisse GroupBoost TargetOutperform$230.00 ➝ $235.00
7/27/2020UBS GroupBoost TargetNeutral$188.00 ➝ $194.00
7/27/2020Deutsche Bank AktiengesellschaftBoost TargetHold$135.00 ➝ $170.00
7/27/2020MizuhoBoost TargetBuy$170.00 ➝ $195.00
7/24/2020Bank of AmericaDowngradeBuy ➝ Neutral
7/24/2020Jefferies Financial GroupBoost TargetBuy$184.00 ➝ $220.00
7/23/2020Credit Suisse GroupBoost TargetOutperform$181.00 ➝ $205.00
4/27/2020SunTrust BanksBoost TargetHold$131.00 ➝ $157.00
4/24/2020Deutsche Bank AktiengesellschaftLower TargetHold$169.00 ➝ $135.00
4/23/2020Credit Suisse GroupLower TargetOutperform$187.00 ➝ $181.00
4/23/2020BarclaysBoost TargetOverweight$170.00 ➝ $180.00
4/20/2020Robert W. BairdDowngradeOutperform ➝ Neutral$151.00
4/9/2020CitigroupLower TargetNeutral$185.00 ➝ $160.00
4/3/2020MizuhoLower TargetBuy$180.00 ➝ $154.00
3/30/2020Wells Fargo & CompanyLower TargetEqual Weight$180.00 ➝ $140.00
3/26/2020BarclaysUpgradeEqual Weight ➝ Overweight$182.00 ➝ $170.00
3/23/2020Jefferies Financial GroupLower TargetBuy$180.00 ➝ $146.00
3/17/2020SunTrust BanksLower TargetHold$182.00 ➝ $131.00
3/2/2020Deutsche Bank AktiengesellschaftInitiated CoverageHold$169.00
2/21/2020UBS GroupBoost TargetNeutral$174.00 ➝ $182.00
2/20/2020BarclaysBoost TargetEqual Weight$168.00 ➝ $182.00
2/20/2020MizuhoReiterated RatingBuy$179.00 ➝ $194.00
1/27/2020SunTrust BanksDowngradeBuy ➝ Hold$170.00 ➝ $182.00
1/7/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$180.00
1/6/2020CitigroupInitiated CoverageNeutral$185.00
(Data available from 10/30/2019 forward)

News Sentiment Rating

0.07 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2024
  • 7 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2024
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2024
  • 3 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2024
  • 1 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2024
  • 4 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2024
  • 4 very positive mentions
  • 21 positive mentions
  • 13 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2024

Current Sentiment

  • 4 very positive mentions
  • 21 positive mentions
  • 13 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

ICON Public logo
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $229.97
Low: $229.57
High: $234.60

50 Day Range

MA: $294.03
Low: $220.47
High: $326.01

52 Week Range

Now: $229.97
Low: $220.01
High: $347.72

Volume

890,582 shs

Average Volume

635,965 shs

Market Capitalization

$18.97 billion

P/E Ratio

26.80

Dividend Yield

N/A

Beta

1.22

Frequently Asked Questions

What sell-side analysts currently cover shares of ICON Public?

The following Wall Street research analysts have issued reports on ICON Public in the last year: Baird R W, Barclays PLC, Citigroup Inc., Evercore ISI, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Mizuho, Redburn Atlantic, Robert W. Baird, StockNews.com, TD Cowen, The Goldman Sachs Group, Inc., Truist Financial Co., and William Blair.
View the latest analyst ratings for ICLR.

What is the current price target for ICON Public?

11 Wall Street analysts have set twelve-month price targets for ICON Public in the last year. Their average twelve-month price target is $304.27, suggesting a possible upside of 30.7%. Evercore ISI has the highest price target set, predicting ICLR will reach $350.00 in the next twelve months. Leerink Partners has the lowest price target set, forecasting a price of $270.00 for ICON Public in the next year.
View the latest price targets for ICLR.

What is the current consensus analyst rating for ICON Public?

ICON Public currently has 3 hold ratings, 10 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ICLR.

What other companies compete with ICON Public?

Other companies that are similar to ICON Public include PPD, Incyte, Exact Sciences, PRA Health Sciences and Charles River Laboratories International. Learn More about companies similar to ICON Public.

How do I contact ICON Public's investor relations team?

ICON Public's physical mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company's listed phone number is (531) 291-2000. The official website for ICON Public is www.iconplc.com. Learn More about contacing ICON Public investor relations.